Cusatuzumab 是一种人αCD70单克隆抗体。 Cusatuzumab 显示出增强抗体依赖性的细胞毒性。 Cusatuzumab 可减少白血病干细胞 (LSC) 并触发与骨髓分化和凋亡apoptosis相关的基因特征。Cusatuzumab 具有研究急性白血病 (AML) 的潜力。
| 生物活性 | Cusatuzumab is a humanαCD70monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation andapoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML)[1]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
